We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+14.47%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.35B
AUM Growth
+$9.88M
Cap. Flow
+$151M
Cap. Flow %
11.19%
Top 10 Hldgs %
48.37%
Holding
65
New
13
Increased
7
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
TECX
Tectonic Therapeutic
TECX
+$45.3M
2
AUTL
Autolus Therapeutics
AUTL
+$40.3M
3
KZR
Kezar Life Sciences
KZR
+$27.4M
4
TCDA
Tricida, Inc. Common Stock
TCDA
+$26.1M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$22.2M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$81.7M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$23.7M
3
YARW
Yarrow Bioscience, Inc. Common Stock
YARW
+$12.7M
4
CLSD
Clearside Biomedical
CLSD
+$7.65M
5
KDMN
Kadmon Holdings, Inc.
KDMN
+$7.01M

Sector Composition

Rank Sector Weight
1 Healthcare 88.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
26
Neurocrine Biosciences
NBIX
$18.7B
$18.8M 1.39%
191,112
– –
VNDA icon
27
Vanda Pharmaceuticals
VNDA
$312M
$18.2M 1.35%
957,821
– –
OMER icon
28
CALL
Omeros
OMER
$863M
$17.6M 1.3%
969,000
– –
RETA
29
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$15.7M 1.16%
450,000
– –
KNSA icon
30
Kiniksa Pharmaceuticals
KNSA
$6.1B
$13.8M 1.02%
+831,000
New +$15M
INCY icon
31
Incyte
INCY
$24.9B
$13.4M 0.99%
+200,000
New +$13.7M
CLSD
32
DELISTED
Clearside Biomedical
CLSD
$12.8M 0.95%
80,000
-45,392
-36% -$7.65M
BOLD
33
DELISTED
Audentes Therapeutics, Inc
BOLD
$12.3M 0.91%
322,945
– –
QTRX icon
34
Quanterix
QTRX
$166M
$12.2M 0.9%
847,788
-1
-0% -$17
INSP icon
35
Inspire Medical Systems
INSP
$1.44B
$11.6M 0.86%
+325,000
New +$10.5M
BHVN
36
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$11.3M 0.83%
284,735
– –
ARRY
37
DELISTED
Array Biopharma Inc
ARRY
$11.2M 0.83%
668,743
– –
MTVA
38
MetaVia Inc
MTVA
$7.44M
$10.6M 0.79%
16
– –
ACRS icon
39
Aclaris Therapeutics
ACRS
$743M
$10.5M 0.78%
525,538
– –
ABEO icon
40
Abeona Therapeutics
ABEO
$369M
$8.79M 0.65%
21,976
– –
ZLAB icon
41
Zai Lab
ZLAB
$2.06B
$7.75M 0.57%
333,166
– –
CFRX
42
DELISTED
ContraFect Corporation
CFRX
$7.5M 0.55%
4,240
– –
EIDX
43
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$7.46M 0.55%
+385,846
New +$8.09M
HRTX icon
44
Heron Therapeutics
HRTX
$94.1M
$7.42M 0.55%
191,108
– –
COLL icon
45
Collegium Pharmaceutical
COLL
$1.17B
$6.84M 0.51%
286,668
– –
TBIO
46
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$5.75M 0.43%
+454,550
New +$5.49M
ITRM
47
DELISTED
Iterum Therapeutics
ITRM
$5.45M 0.4%
+33,333
New +$6.02M
SGMO
48
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5.43M 0.4%
382,192
– –
NERV icon
49
Minerva Neurosciences
NERV
$187M
$5.01M 0.37%
75,988
– –
XLRN
50
DELISTED
Acceleron Pharma
XLRN
$3.48M 0.26%
71,667
– –
1
2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q2 2018 Portfolio in Review

As of Q2 2018, Cormorant Asset Management held 65 positions worth $1.35B, up 0.74% from $1.34B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Cormorant Asset Management deployed $151M of net new capital in Q2 2018, opening 13 new positions and adding to 7 existing holdings. Its largest new stake was Tectonic Therapeutic: 125,649 shares worth $43.1M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 83% a quarter earlier.

On the sell side, the largest reduction was Nektar Therapeutics, an estimated $81.7M trimmed.

  • Cormorant Asset Management's largest Q2 2018 buy was Tectonic Therapeutic: 125,649 shares worth $43.1M.
  • Cormorant Asset Management added most to Arena Pharmaceuticals Inc in Q2 2018, an estimated $14M increase.
  • Cormorant Asset Management's biggest Q2 2018 reduction was Nektar Therapeutics, cutting an estimated $81.7M.
  • Cormorant Asset Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $23.7M.
  • Cormorant Asset Management's ten largest holdings make up 48% of its $1.35B portfolio in Q2 2018.
  • Cormorant Asset Management opened 13 new positions and closed 7 in Q2 2018.
  • Cormorant Asset Management's portfolio value rose 0.74% quarter-over-quarter to $1.35B.

Based on Cormorant Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.